Clinical efficacy of TACE combined with ultrasound-guided radiofrequency ablation in the treatment of primary liver cancer
Objective To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with ultrasound-guided percutaneous radiofrequency ablation and hepatic arterial embolization(TACE)on clinical efficacy and liver function in patients with primary liver cancer.Methods A total of 100 patients with primary liver cancer admitted to our hospital from May 2019 to June 2021 were randomly divided into two groups:control group and Observa-tion Group.Fifty patients with primary liver cancer were treated with TACE only in the control group,and the other 50 patients were treated in the Observation Group,that was treated with ultrasound guided percutaneous radiofrequency ablation and TACE.The liver function,clinical efficacy,adverse reaction and survival rate were compared between the two groups.Results After treatment,the levels of ALT,AST,total bilirubin and AFP in the observation group were signifi-cantly lower than those in the control group,and the short-term effective rate was 76%in the Observation Group,48%in the control group,and the difference was significant(χ2 = 8.319,P = 0.004);the progression-free survival time was(12.13±2.95)months in the observation group and(9.05±3.73)months in the control group,and the difference was significant(t=3.237,P<0.05).The 1-year survival rate of the observation group(90%)was higher than that of the control group(58%),the difference was statistically significant(χ2=13.306,P<0.05).The incidence of complications in the observation group was higher than in the control group(χ2 = 4.456,P=0.035).Conclusion TACE combined with ultrasound-guided percutaneous radiofrequency ablation in the treatment of primary liver cancer has a significant clinical effect,can improve liver function to a certain extent,and has a broad and good clinical application prospect.
NETL
NSTL
万方数据
